Analysis of 1261 metastatic cancer patients evaluated by comprehensive molecular profiling (CMP) including next-gen sequencing (NGS) from a single institution.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 11570-11570 ◽  
Author(s):  
Jason Claud Chandler ◽  
Ari M. Vanderwalde ◽  
Bradley G. Somer ◽  
Gregory A. Vidal ◽  
Lee Steven Schwartzberg
Keyword(s):  
Cancer Patients ◽  
Metastatic Cancer ◽  
Molecular Profiling ◽  
Single Institution ◽  
Next Gen Sequencing

Feasibility and clinical utility of molecular profiling among metastatic cancer patients: A cancer center experience in Philippines.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e22132-e22132
Author(s):  
Herdee Gloriane Cristal Luna ◽  
Amherstia Morelos ◽  
Mary Milisa Catedral ◽  
Ana Lea Lava ◽  
April Love Malasig ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Clinical Utility ◽  
Metastatic Cancer ◽  
Molecular Profiling ◽  
Cancer Center

274 High-dose medroxyprogesterone acetate (MPA) in metastatic cancer patients

1983 ◽  
Vol 19 ◽  
pp. 91
Author(s):  
P. Schmidt-Rhode ◽  
G. Sturm ◽  
K.-D. Schulz ◽  
H.J. Künzig ◽  
M. Wunsch
Keyword(s):  
Cancer Patients ◽  
Medroxyprogesterone Acetate ◽  
Metastatic Cancer ◽  
High Dose

scholarly journals CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience

2021 ◽  
Vol 9 (2) ◽  
pp. 42
Author(s):  
Angeliki Andrikopoulou ◽  
Oraianthi Fiste ◽  
Kleoniki Apostolidou ◽  
Efthymia Skafida ◽  
Christos Markellos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Small Sample Size ◽  
Small Sample ◽  
Musculoskeletal Symptoms ◽  
Hematological Toxicity ◽  
Breast Cancer Patients ◽  
Single Institution ◽  
Duration Of Treatment ◽  
Positive Breast Cancer

Background: Aromatase inhibitors (AIs) are associated with musculoskeletal pain in one third (20–47%) of breast cancer patients. Recently, CDK4/6 inhibitors have emerged as a new therapeutic approach in hormone receptor (HR)-positive breast cancer. While hematological and gastrointestinal toxicities are frequently reported during treatment with CDK4/6 inhibitors, musculoskeletal symptoms are less commonly encountered. Methods: Herein, we present a retrospective study of 47 breast cancer patients who received CDK4/6 inhibitors along with endocrine therapy in our department between 01/01/2018 and 01/09/2020. Results: Median age at diagnosis was 58 years (29–81). Median duration of treatment was 8.76 months (SD: 7.68; 0.47–30.13 months). Median PFS was 24.33 months (95% CI; 1.71–46.96). Overall, toxicity was reported in 61.7% of the cases (29/47). Arthralgia was reported in 6.4% (3/47) of the patients. Hematological toxicity was reported in 51.1% (24/47) of the patients. Neutropenia was the main hematological toxicity observed (86.8%; 22/47) along with anemia (4.3%; 2/47), thrombocytopenia (2.1%; 1/47), and leukopenia (4.2%; 1/24). Conclusions: Though our data reflect a small sample size, we report a reduced arthralgia rate (6.4%) during treatment with CDK4/6 inhibitors compared with that reported in studies of AIs (20–47%).

Sign in / Sign up

Export Citation Format

Share Document